As IFN-γ signaling is an integral part of anti-tumor immunity, these lncRNAs, in particular lncRNA EPIC1 due to its pan-cancer applicability, may represent a promising target for therapeutic intervention. This evidence concerns the gene IFNG and neoplasm.